Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma

Table 2 Correlation among fibroblast growth factor receptor 1 amplification, MYC expression and clinicopathological features¹

Variables	FGFR1, n (%)			MYC, n (%)
	No amplification	Amplification	P value	No expression	Expression	P value
Age (yr)
≤ 60	30/44 (68.2)	14/44 (31.8)	0.058	18/46 (39.1)	28/46 (60.9)	0.862
> 60	106/129 (82.2)	23/129 (17.8)		56/134 (41.8)	78/134 (58.2)
Smoking
No	21/28 (75)	7/28 (25)	0.619	12/28 (42.9)	6/28 (57.1)	0.836
Yes	115/145 (79.3)	30/145 (20.7)		61/151 (40.4)	90/151 (59.6)
Histological grade
WD	29/34 (85.3)	5/34 (14.7)	0.350	17/35 (48.6)	18/35 (51.4)	0.267
MD	90/117 (76.9)	27/117 (23.1)		43/119 (36.1)	76/119 (63.9)
PD	11/16 (68.8)	5/16 (31.2)		10/18 (55.6)	8/18 (44.4)
Others	6/6 (100)	0/6 (0)		4/8 (50)	4/8 (50)
Localization
Upper	6/7 (85.7)	1/7 (14.3)	0.981	4/7 (57.1)	3/7 (42.9)	0.688
Middle	34/42 (81)	8/42 (19)		20/44 (45.5)	24/44 (54.5)
Lower	86/111 (77.5)	25/111 (22.5)		45/116 (38.8)	71/116 (61.2)
EGJ	8/10 (80)	2/10 (20)		4/10 (40)	6/10 (60)
T
1	66/80 (82.5)	14/80 (17.5)	0.602	22/81 (27.2)	59/81 (72.8)	< 0.001
2	12/16 (75)	4/16 (25)		6/17 (35.3)	11/17 (64.7)
3	55/73 (75.3)	18/73 (24.7)		43/78 (55.1)	35/78 (44.9)
4	3/4 (75)	1/4 (25)		3/4 (75)	1/4 (24)
N
0	73/90 (81.1)	17/90 (18.9)	0.460	30/92 (32.6)	62/92 (67.4)	0.023
1-3	63/83 (75.9)	20/83 (24.1)		44/88 (50)	44/88 (50)
Stage
I	51/62 (82.3)	11/62 (17.7)	0.694	18/63 (28.6)	45/64 (71.4)	< 0.001
II	40/52 (76.9)	12/52 (23.1)		17/53 (32.1)	36/53 (67.9)
III	45/59 (76.3)	14/59 (23.7)		39/64 (60.9)	25/64 (39.1)

¹Differences in the proportions of fibroblast growth factor receptor 1 (FGFR1) amplification and MYC expression according to the clinicopathological variables were compared using Fisher’s exact test. WD: Well differentiated; MD: Moderately differentiated; PD: Poorly differentiated; EGJ: Esophagogastric junction.